ACER - オペクサ・セラピュ―ティクス (Acer Therapeutics Inc.) オペクサ・セラピュ―ティクス

 ACERのチャート


 ACERの企業情報

symbol ACER
会社名 Acer Therapeutics Inc (オペクサ・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 オペクサ・セラピューティクス(Opexa Therapeutics Inc)はバイオ医薬品企業。同社は多発性硬化症(MS)などの疾患に対する治療の可能性のある個別化細胞療法の開発に従事する。それらの治療法は同社のT細胞技術をベースとしている。同社の主な製品候補であるTovaxinはベーラー医科大学(Baylor College of Medicine)からライセンスを受けた、MS治療用の臨床開発中の個別化T細胞治療ワクチンである。TcelnaはT細胞の免疫療法であり、IIb期臨床開発中の二次進行型MS(SPMS)治療用に使用される。Tcelnaは患者の疾患プロファイルに特に合わせる個人向け治療法である。TERMS研究は臨床分離症候群リスクの高いあるいは再発寛解型多発性硬化症(RRMS)を患っている150位患者を対象とする多中心の無作為プラセボ比較二重盲検臨床試験である。   オペクサ・セラピュ―ティクスは米国のバイオ医薬品会社。多発性硬化症(MS)など重篤な疾病、及び視神経脊髄炎などの免疫性疾患の自己免疫療法の開発に従事。独自に開発したT細胞技術に基づき、二次進行型MSや再発寛解型MSなどの治療薬の臨床開発段階にある。また、血液から単球由来幹細胞を生成するための成体幹細胞技術を開発。本社はテキサス州。   Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Acer's pipeline includes four programs: ACER-001 (a taste-masked, immediate release formulation of sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); emetine hydrochloride, a host-directed therapy against a variety of infectious diseases, initially for the treatment of patients with COVID-19; EDSIVO™ (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and osanetant for the treatment of induced Vasomotor Symptoms (iVMS). Each of Acer's product candidates is believed to present a comparatively de-risked profile, having one or more of a favorable safety profile, clinical proof-of-concept data, mechanistic differentiation and/or accelerated paths for development through specific programs and procedures established by the FDA.
本社所在地 One Gateway Center Suite 351 300 Washington St. Newton MA 02458 USA
代表者氏名
代表者役職名
電話番号
設立年月日 33298
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 6人
url www.acertx.com
nasdaq_url https://www.nasdaq.com/symbol/acer
adr_tso
EBITDA EBITDA(百万ドル) -16.45878
終値(lastsale) 28.37
時価総額(marketcap) 285203269.56
時価総額 時価総額(百万ドル) 282.99160
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 274.64783
当期純利益 当期純利益(百万ドル) -16.51118
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Acer Therapeutics Inc revenues was not reported. Net loss increased 36% to $8.8M. Higher net loss reflects General and administrative increase from $1.5M to $4.1M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.01 to -$1.18.

 ACERのテクニカル分析


 ACERのニュース

   Comparing Acer Therapeutics (NASDAQ:ACER) and CV Sciences (OTCMKTS:CVSI)  2021/12/12 06:12:42 Dakota Financial News
Acer Therapeutics (NASDAQ:ACER) and CV Sciences (OTCMKTS:CVSI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk. Profitability This table compares Acer Therapeutics and CV Sciences net margins, return on equity and []
   Acer Therapeutics wins FDA nod for hot flashes trial  2021/12/09 14:21:04 Seeking Alpha
   Acer Therapeutics Announces ACER-801 IND Clearance for the Treatment of Induced Vasomotor Symptoms  2021/12/09 13:30:00 Intrado Digital Media
Phase 2a trial initiation expected in Q1 2022
   Acer Therapeutics (NASDAQ:ACER) Stock Rating Upgraded by Zacks Investment Research  2021/12/09 08:36:41 Transcript Daily
Acer Therapeutics (NASDAQ:ACER) was upgraded by Zacks Investment Research from a sell rating to a hold rating in a report issued on Tuesday, Zacks.com reports. According to Zacks, Acer Therapeutics Inc. is a pharmaceutical company. It develops therapies for the treatment of ultra-rare diseases with critical unmet medical need. The companys product pipeline consists of []
   -$0.24 Earnings Per Share Expected for Acer Therapeutics Inc. (NASDAQ:ACER) This Quarter  2021/12/05 14:46:42 Dakota Financial News
Equities analysts expect that Acer Therapeutics Inc. (NASDAQ:ACER) will announce earnings of ($0.24) per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Acer Therapeutics earnings. The lowest EPS estimate is ($0.25) and the highest is ($0.22). Acer Therapeutics posted earnings of ($0.50) per share during the same []
   Black Friday Alienware Deals (2021): Top Early Alienware x15 Laptop, 1080p Monitor & More Savings Identified by Consumer Walk  2021/11/08 09:40:00 Kwhen Finance
   Black Friday Gaming PC Deals (2021): Early NZXT, CyberPowerPC & More Gaming Computer Savings Reviewed by Consumer Walk  2021/11/07 12:30:00 Kwhen Finance
   Black Friday Gaming Monitor Deals 2021: Early Curved, 27 Inch, 4K & More Sales Published by Saver Trends  2021/11/07 11:50:00 Kwhen Finance
   Best Black Friday Gaming Laptop Deals 2021: Best Early ASUS, HP, Acer & More Laptop Savings Summarized by Deal Tomato  2021/11/07 10:40:00 Kwhen Finance
   Chromebook Black Friday Deals (2021): Early Acer, Lenovo, ASUS & More Sales Ranked by Retail Fuse  2021/11/06 14:05:00 Kwhen Finance
   Here is What Hedge Funds Think About Acer Therapeutics Inc. (ACER)  2021/06/13 18:11:56 Insider Monkey
   Acer Therapeutics (ACER) Receives a Hold from Needham  2021/06/11 19:15:07 Smarter Analyst
Needham analyst Serge Belanger maintained a Hold rating on Acer Therapeutics (ACER) today. The companys shares closed last Friday at $3. The post Acer Therapeutics (ACER) Receives a Hold from Needham appeared first on Smarter Analyst .
   Acer Therapeutics plans clinical trial of Edsivo in connective-tissue disorder  2021/06/10 13:14:21 Seeking Alpha
   Acer Therapeutics Plans Clinical Trial for EDSIVO (celiprolol) Following Type B FDA Meeting  2021/06/10 12:30:00 Wallstreet:Online
Phase 3, randomized, double-blind, placebo-controlled, decentralized clinical trial estimated to take approximately 3.5 years to complete once fully enrolled FDA indicates agreement with submission of proposed protocol under a Special Protocol Assessment (SPA) with possible breakthrough designation NEWTON, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical
   Acer Therapeutics plans NDA submission for ACER-001 in Q3 2021  2021/05/25 12:48:36 Seeking Alpha

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 オペクサ・セラピュ―ティクス ACER Acer Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)